Glorikian Publications
Even as Testing Demand Started to Wane, COVID-19 Drove IPOs…
COVID-19 testing problems started early, U.S. still playing from behind…
Clinical Trial Protocol Design Gets Patient Input Boost from Transparency…
It’s a Connected World’: How To Face the Data Firehose…
NextGen Healthcare: The problem isn’t genomics by Harry Glorikian, a…
Listent to Episode Here: http://fticorporate.com/podcasts/harry-glorikian/ Diving with Data – Episode 11:…
What we pay for in healthcare is the real question…
Healthcares Digital future: Telemedicine and remote monitoring Every week, news…
MONEYBALL MEDICINE PRICE QUALITY TRANSPARENCY Say you want to open…
Leadership Series: Interview with Harry Glorikian, Partner at New Ventures…
Welcome to the age of Moneyball Medicine For several years,…
My Love Letter to Tech It’s the start of the…
Transforming the Bioresearch and Healthcare Industries Technology and Data Usher…
Why do IVD companies face a battle with payers for…
Intellectual property considerations for molecular diagnostic development with emphasis on…
MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market How…
The MoneyBall solution to the healthcare crisis Many recent articles…
What’s THE Key to efficient IVD development? In the quest…
Data and IVD’s requirements in a value-based reimbursement landscape The…
This is why pre-design research is essential for the IVD…